Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call Transcript
Greetings. Welcome to the Relmada Therapeutics results of registrational Phase III RELIANCE I trial for REL-1017 as an adjunctive treatment for major depressive disorder.
(Operator Instructions)
Please note, this conference is being recorded. And I will now turn the conference over to your host Timothy McCarthy of LifeSci Advisors, you may begin.
Thank you, Shomali, and thank you all for joining us this afternoon. With me on today's call are Relmada's Chief Executive Officer; Sergio Traversa; Maged Shenouda, Relmada's Chief Financial Officer; Dr. Paolo Manfredi, Relmada's Chief Scientific Officer; and RELIANCE Program Principal Investigator, Dr. Maurizio Fava, the Chairman of Harvard's Psychiatry Department.
Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
